Image correction in Current Biology for Harvard’s Sam Lee

The work of Sam W. Lee, a cancer biologist at Harvard and Massachusetts General Hospital, has come under fire at Science Fraud lately over concerns about the possible reuse of images in his group’s published studies.

Turns out there’s some there, there after all. The journal Current Biology has issued a pretty thorny correction for one of Lee’s 2006 articles, “RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress,” citing multiple issues with its figures: Continue reading Image correction in Current Biology for Harvard’s Sam Lee

Accounting fraud paper retracted for “misstatement”

The Accounting Review, a publication of the American Accounting Association, has retracted a 2010 paper, but the reason for the move is less than clear.

The article, “A Field Experiment Comparing the Outcomes of Three Fraud Brainstorming Procedures: Nominal Group, Round Robin, and Open Discussion,” was by James E. Hunton, an award-winning accountancy prof at Bentley University in Waltham, Mass., and Anna Gold [updated 1/22/13 to update link], of Erasmus University in Rotterdam, The Netherlands. It has been cited 24 times, according to Google Scholar.

According to the retraction notice: Continue reading Accounting fraud paper retracted for “misstatement”

Chemistry journal and author retract paper dogged by questions since its publication in 2006

A chemistry journal has retracted a 2006 paper that had knowledgeable researchers scratching their heads from the minute it was published.

Here’s the notice: Continue reading Chemistry journal and author retract paper dogged by questions since its publication in 2006

You’ve been dupe’d: Catching up on authors who liked their work enough to use it again

photo by Mark Turnauckas via Flickr http://www.flickr.com/photos/marktee/

As we’ve noted before, we generally let duplication retractions make their way to the bottom of our to-do pile, since there’s often less of an interesting story behind them, duplication is hardly the worst of publishing sins, and the notices usually tell the story. (These are often referred to — imprecisely — as “self-plagiarism.”)

But that skews what’s represented here — boy, are there a lot of duplication retractions we haven’t covered! — and we might as well be more comprehensive. Plus, our eagle-eyed readers may find issues that we won’t see on a quick scan.

So with this post, we’re inaugurating a new feature here at Retraction Watch, “You’ve been dupe’d.” Every now and then, we’ll gather five of these duplication retractions at a time, and post them so they get into the mix, and into our category listing (see drop-down menu in right-hand column if you haven’t already). Here are the first five: Continue reading You’ve been dupe’d: Catching up on authors who liked their work enough to use it again

Pfizer retracts study of experimental cancer treatment figitumumab for incorrect analyses

Pfizer has retracted a 2009 Journal of Clinical Oncology study purporting to show a benefit of their experimental drug for lung cancer figitumumab after discovering that its clinical lead on the project had done analyses improperly.

Here’s the text of the notice: Continue reading Pfizer retracts study of experimental cancer treatment figitumumab for incorrect analyses

ORI investigating University of Florida ob-gyn researcher accused of misconduct

A prominent researcher at the University of Florida is under federal investigation for research misconduct and has lost at least one paper as a result of the fraud.

The researcher, Nasser Chegini, was a professor of obstetrics and gynecology at the U of Florida until about six months ago, when he retired, according to the chair’s office. Nasser has received at least $4 million in federal grant funding, according to the university.

The retracted paper, “MicroRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells,” was published in 2010 by Molecular Human Reproduction. The authors were Qun Pan and Xiaoping Luo and Chegini.

As the notice explains: Continue reading ORI investigating University of Florida ob-gyn researcher accused of misconduct

High school whiz kid retracts PLoS ONE herd immunity paper

Georgette speaking at the Davidson Institute’s award ceremony, Library of Congress, 2008

It’s pretty impressive to publish two peer-reviewed papers on complicated vaccination models while you’re still in high school. So it’s not surprising that Nathan Georgette, who grew up outside of Jacksonville, Florida, earned a prestigious fellowship from the Davidson Institute for Talent Development.

But perhaps even more impressive is realizing you’ve made a fundamental error in one of those studies, and retracting it while you’re still a college senior at Harvard. Continue reading High school whiz kid retracts PLoS ONE herd immunity paper

Correction for MD Anderson’s Bharat Aggarwal arches eyebrows for the right reasons

We’ve written about mega-corrections that allow scientists to retrace virtually all of their steps yet preserve their publications as supposedly legitimate. And we’ve seen plenty of corrections that allow authors to assert that their conclusions are correct when evidently important pieces of data are themselves unreliable.

Now comes a correction that seems to us to strike the right chords, given the fact that editors are to a large extent at the mercy of authors in these situations. Continue reading Correction for MD Anderson’s Bharat Aggarwal arches eyebrows for the right reasons

The domino effect: More retractions of papers that cited retracted PLoS ONE GMO cassava study

Last month, we reported on a PLoS ONE paper about genetically modified cassava — or, more correctly, allegedly GMO cassava — that was being retracted because data “could not be found.” We have an update on that story, namely that a paper relying on materials from that lab will be retracted, and that authors of a review that included a figure from the graduate student who claimed to have done the work will retract part of their paper.

As a Retraction Watch commenter on our earlier post noted, referring to Claude Fauquet, the PI of the Danforth Center lab where graduate student Mohammad Abhary worked: Continue reading The domino effect: More retractions of papers that cited retracted PLoS ONE GMO cassava study

Another retraction for Anil Potti, with an inscrutable notice

We’ve seen a lot of retraction notices for work by Anil Potti — 10, to be precise, along with 7 corrections and one partial retraction notice. As notices go, they tend to be pretty complete. So when we saw one in CHEST for this 2008 abstract, we were expecting something similar.

Instead, we were confused.

Here’s the notice: Continue reading Another retraction for Anil Potti, with an inscrutable notice